GATEWAY 2026
Threehorizons.
One company,
three doors.
Your bridge between the world and Japan's pharmaceutical & health industry.
7+
COUNTRIES
9+
PARTNERS
2023
FOUNDED
3
DOORS
Care Link
Specialty Pharma × Last Mile
Delivering directly to patients
Last-mile delivery of specialty pharmaceuticals from pharmacies to patient homes. End-to-end cold chain management, adherence monitoring, and PSP integration.
Global Bridge
Import × Export
A two-way bridge between Japan and the world
Japan market entry for overseas pharma and raw materials. Global expansion for Japanese OTC and supplements. Regulatory to logistics, end-to-end.
garden
Supplement Development
From idea to product
Supplement and health food planning to manufacturing. OEM/ODM, raw material sourcing, and branding support.
Latest Insights
Healthcare insights shared by CEO Masaya Yamamoto on NewsPicks
糖尿病「第4の細小血管症」― 肺機能低下を加える前に問うべきこと
At EASD 2026, a proposal emerged to classify pulmonary function decline as a 'fourth microvascular complication' of diabetes, alongside retinopathy, nephropathy, and neuropathy—conditions long managed under the principle of early, pre-symptomatic detection and intervention. If lung function deterioration also progresses silently, the same logic would seem to apply. That said, I am not convinced that spirometry should simply be added to the standard follow-up panel: the test is highly effort-dependent, maintaining reliable results across a busy diabetes clinic demands considerable staff time and training, and the evidence base for interventions that would actually improve prognosis after early detection remains thin. Before expanding screening, I would first want to assess how consistently the existing three-complication screens are being completed, and use that as a benchmark for gauging the priority of adding pulmonary assessment. Whether 'the fourth complication' takes hold as a clinical concept will ultimately depend on whether we can point to meaningful next steps once the finding is made.
予防神経学の可能性と日本の制度的課題 ― 科学が先行する現状をどう変えるか
The framework of 'preventive neurology' invites us to stop treating cognitive decline as an inevitable consequence of aging and to start managing it proactively. The 2024 Lancet Commission report's finding that 45% of dementia risk is modifiable is backed by multi-domain intervention studies such as FINGER and U.S. POINTER, while the observation that midlife hearing loss alone accounts for 7% of modifiable risk challenges existing health-screening systems that have long deprioritized sensory care. That said, implementation in Japan calls for sober assessment. Adhering to the MIND diet, individualizing exercise prescriptions, and reviewing medications using the ACB scale all demand time and expertise, yet there is no clear pathway to embed these into the current framework of specific health checkups and lifestyle guidance. For primary care physicians to take on ongoing cognitive prevention, both appropriate remuneration and sufficient consultation time are prerequisites. Dr. Spević's remark—'I can hand out a pamphlet, but what truly matters is habit formation'—captures the clinical reality precisely, yet the question of whether it is acceptable to leave that habit formation entirely to individual willpower remains open. We need to advance, in parallel, a conversation about how to close the gap between science that races ahead and policy that lags behind.
医療DX時代のサイバー攻撃 ― サプライチェーン全体の信頼設計が急務
Large-scale data breaches in the medical and healthcare sector continue to mount, and the latest incident at an Asahi Kasei subsidiary—affecting up to 550,000 people—demands serious attention in the context of Japan's push for healthcare digitalization. What concerns me most is the nature of the data exposed: healthcare records are easily linked to highly sensitive personal information such as medical history, prescription records, and lifestyle data. Once that information leaks, it can lead to disadvantages in insurance enrollment or employment—a social impact of an entirely different dimension from financial data breaches. The core issue, I believe, is not simply the sophistication of technical defenses. What truly matters is whether security governance across the entire supply chain—including contractors and sub-contractors—is structurally sound. The more companies handle medical data, the more likely a 'weakest link' will emerge somewhere in that chain. We must keep asking how to design systems that preserve trust while capturing the benefits of digitalization; we cannot afford to accelerate data utilization while looking away from that question.